A retrospective follow-up study demonstrates that tandem autologous-allogeneic is safe for standard and high-risk multiple myeloma. However, benefits do not extend to patients with ultra-high-risk disease and those with disease progression after autologous HCT.
A review of granulocyte colony-stimulating factors, dosage and administration, adverse effects, and nurse management steps is presented.
Among long-term survivors of hematopoetic cell transplantation (HCT), patient-reported resilience is independently associated with outcomes.
Overall US cancer death rates have continued to decline since the early 1990s, but excess weight and lack of sufficient activity contribute to the increased incidence of many cancers.
